Hinduja Backed Firm MindMaze Garners $105 Million from Concord Health Partners
MindMaze, a worldwide pioneer in the multibillion-dollar digital neurotherapeutics sector and a Hinduja-backed company, has garnered $105 million in funding to drive its global commercial expansion goals and continued R&D.
This will also help to streamline the company's clinical development pipeline for its industry-leading digital therapeutic solutions for a variety of neurological illnesses.
The round of funding gives immediate access to capital as well as a financing arrangement to support future acquisitions and expansion. Along with other investors, the financing was headed by Concord Health Partners ("Concord"), a US-based healthcare private equity firm focusing on investing in and supporting healthcare firms with breakthrough technology and solutions that address quality, affordability, and access to treatment.
AlbaCore Capital Group, one of Europe's top specialised investors specialising in public and private markets, is increasing their current investment as a sign of their sustained support for the company. Hambro Perks, a London-based investor with strong industry experience and a worldwide portfolio of revolutionary, highly scalable firms, as well as many family office investment groups, participated in this round.
MindMaze will also form a collaboration with The American Hospital Association ("AHA") as a result of Concord's investment. The AHA is dedicated to the growth of innovative healthcare solutions and acts as a national champion for its provider member organisations, which include over 90% of US hospitals, health systems, and other health care organisations, as well as 300,000 health care executives.
MindMaze, supported by Hinduja, is ushering in a new era of medicine by addressing major cognitive and mobility deficiencies using unique tech-enabled protocolized software and hardware peripherals. The fundraising announcement comes on the heels of a huge milestone for reimbursement with Category III codes for asynchronous treatment, confirming the company's status as a digital neurotherapeutics pioneer. Millions of patients and caregivers throughout the world will benefit from the Company's innovations. Leonardo Dicaprio is also a supporter of the project.
According to Ajay P Hinduja, a member of the Hinduja family's third generation, “We believe in empowering technologies that can lead to global transformation, and MindMaze’s brain technology platform will deliver breakthrough solutions that will redefine brain health and have a global impact. We are entirely devoted to assisting the company’s success in the coming years and bring sustainable, transformational technology to the healthcare sector in all global markets including India.”
MindMaze's Founder and CEO, Tej Tadi, stated, “This funding allows us to ramp up commercial activity and expand our footprint in the U.S, as well as gain access to strategic partners as we continue to deploy solutions across the continuum of care globally.”
He added, “MindMaze has been at the frontier of brain tech since its inception, and we’ve been an essential part of the incredible advancements over the last decade across brain sensing, motion capture, mixed reality platforms, new architectures for brain inspired computing and machine learning/AI. We are thrilled that our incredibly supportive partners at AlbaCore will be increasing their investment in MindMaze and pleased that important strategic growth investors, such as Concord Health Partners and the larger investment community, see the broad- reaching potential of our digital neurotherapeutics platform as we continue to accelerate humanity’s ability to recover, learn, and adapt.”
Concord's Founder and Managing Partner, James Olsen, stated, “MindMaze has developed the leading technology and approach to digital therapeutics for neuro-rehabilitation and restoration, providing clear benefits to patients, providers and payors. We believe this notable advancement in treatment and therapy will meaningfully improve brain health and recovery for a wide range of conditions. We are thrilled to partner with Tej and the MindMaze team to build on its impressive track record and to support clinical and commercial expansion in the US market.”
The American Hospital Association's Senior Vice President of Business Development, Doug Shaw, stated, “The AHA is excited to join initiatives to promote and advance the delivery of digital therapeutic solutions for neurological diseases in accessible settings, and MindMaze will enable our hospitals, health care systems and other providers of care to offer new, innovative solutions to help treat their patients.”
MindMaze, which is funded by Hinduja, is ISO 13485 certified, with three FDA approvals and four CE marks across several therapeutic indications. The company, which operates in more than twenty countries, provides thousands of patients with neurological diseases with seamless digital evaluations and medicines across the whole continuum of care.
This will also help to streamline the company's clinical development pipeline for its industry-leading digital therapeutic solutions for a variety of neurological illnesses.
The round of funding gives immediate access to capital as well as a financing arrangement to support future acquisitions and expansion. Along with other investors, the financing was headed by Concord Health Partners ("Concord"), a US-based healthcare private equity firm focusing on investing in and supporting healthcare firms with breakthrough technology and solutions that address quality, affordability, and access to treatment.
AlbaCore Capital Group, one of Europe's top specialised investors specialising in public and private markets, is increasing their current investment as a sign of their sustained support for the company. Hambro Perks, a London-based investor with strong industry experience and a worldwide portfolio of revolutionary, highly scalable firms, as well as many family office investment groups, participated in this round.
MindMaze will also form a collaboration with The American Hospital Association ("AHA") as a result of Concord's investment. The AHA is dedicated to the growth of innovative healthcare solutions and acts as a national champion for its provider member organisations, which include over 90% of US hospitals, health systems, and other health care organisations, as well as 300,000 health care executives.
MindMaze, supported by Hinduja, is ushering in a new era of medicine by addressing major cognitive and mobility deficiencies using unique tech-enabled protocolized software and hardware peripherals. The fundraising announcement comes on the heels of a huge milestone for reimbursement with Category III codes for asynchronous treatment, confirming the company's status as a digital neurotherapeutics pioneer. Millions of patients and caregivers throughout the world will benefit from the Company's innovations. Leonardo Dicaprio is also a supporter of the project.
According to Ajay P Hinduja, a member of the Hinduja family's third generation, “We believe in empowering technologies that can lead to global transformation, and MindMaze’s brain technology platform will deliver breakthrough solutions that will redefine brain health and have a global impact. We are entirely devoted to assisting the company’s success in the coming years and bring sustainable, transformational technology to the healthcare sector in all global markets including India.”
MindMaze's Founder and CEO, Tej Tadi, stated, “This funding allows us to ramp up commercial activity and expand our footprint in the U.S, as well as gain access to strategic partners as we continue to deploy solutions across the continuum of care globally.”
He added, “MindMaze has been at the frontier of brain tech since its inception, and we’ve been an essential part of the incredible advancements over the last decade across brain sensing, motion capture, mixed reality platforms, new architectures for brain inspired computing and machine learning/AI. We are thrilled that our incredibly supportive partners at AlbaCore will be increasing their investment in MindMaze and pleased that important strategic growth investors, such as Concord Health Partners and the larger investment community, see the broad- reaching potential of our digital neurotherapeutics platform as we continue to accelerate humanity’s ability to recover, learn, and adapt.”
Concord's Founder and Managing Partner, James Olsen, stated, “MindMaze has developed the leading technology and approach to digital therapeutics for neuro-rehabilitation and restoration, providing clear benefits to patients, providers and payors. We believe this notable advancement in treatment and therapy will meaningfully improve brain health and recovery for a wide range of conditions. We are thrilled to partner with Tej and the MindMaze team to build on its impressive track record and to support clinical and commercial expansion in the US market.”
The American Hospital Association's Senior Vice President of Business Development, Doug Shaw, stated, “The AHA is excited to join initiatives to promote and advance the delivery of digital therapeutic solutions for neurological diseases in accessible settings, and MindMaze will enable our hospitals, health care systems and other providers of care to offer new, innovative solutions to help treat their patients.”
MindMaze, which is funded by Hinduja, is ISO 13485 certified, with three FDA approvals and four CE marks across several therapeutic indications. The company, which operates in more than twenty countries, provides thousands of patients with neurological diseases with seamless digital evaluations and medicines across the whole continuum of care.
.jpg "Multycomm : Streamlining Enterprise Communications for an Enhanced Customer Experience & Brand Connect")
